Growth Metrics

Vertex Pharmaceuticals (VRTX) Long-Term Deferred Tax (2017 - 2025)

Historic Long-Term Deferred Tax for Vertex Pharmaceuticals (VRTX) over the last 9 years, with Q3 2025 value amounting to $2.9 billion.

  • Vertex Pharmaceuticals' Long-Term Deferred Tax rose 2721.21% to $2.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 billion, marking a year-over-year increase of 2721.21%. This contributed to the annual value of $2.3 billion for FY2024, which is 2864.08% up from last year.
  • Per Vertex Pharmaceuticals' latest filing, its Long-Term Deferred Tax stood at $2.9 billion for Q3 2025, which was up 2721.21% from $2.7 billion recorded in Q2 2025.
  • In the past 5 years, Vertex Pharmaceuticals' Long-Term Deferred Tax registered a high of $2.9 billion during Q3 2025, and its lowest value of $815.9 million during Q1 2021.
  • In the last 5 years, Vertex Pharmaceuticals' Long-Term Deferred Tax had a median value of $1.5 billion in 2023 and averaged $1.7 billion.
  • As far as peak fluctuations go, Vertex Pharmaceuticals' Long-Term Deferred Tax plummeted by 2891.12% in 2021, and later soared by 4871.42% in 2023.
  • Quarter analysis of 5 years shows Vertex Pharmaceuticals' Long-Term Deferred Tax stood at $934.5 million in 2021, then surged by 33.43% to $1.2 billion in 2022, then surged by 45.33% to $1.8 billion in 2023, then grew by 28.64% to $2.3 billion in 2024, then grew by 26.0% to $2.9 billion in 2025.
  • Its Long-Term Deferred Tax stands at $2.9 billion for Q3 2025, versus $2.7 billion for Q2 2025 and $2.5 billion for Q1 2025.